Why Don’t Edibles Work for Me? Cannabis Metabolism and CYP2C9 Genetics

You eat a cannabis edible. Your friend feels it in 45 minutes. Two hours later, you feel nothing. You double the dose. Then it hits all at once — too hard, too late. Or it never does. You try again the next week, same brand, same dose, and the experience is completely different. This is not tolerance. This is not placebo. This is genetics.

The enzymes that metabolize THC — the primary psychoactive compound in cannabis — vary dramatically from person to person based on inherited genetic variants. These differences are especially pronounced with edibles, because edibles go through a metabolic process that smoking and vaping bypass entirely.

The First-Pass Effect: Why Edibles Are Different from Smoking

When you smoke or vape cannabis, THC enters your lungs and passes directly into your bloodstream. It reaches your brain within minutes. Your liver processes it later, on the back end, after the effects have already started.

Edibles take a completely different route. THC is absorbed through your gut, enters the portal vein, and goes straight to your liver before ever reaching your brain. This is called the first-pass effect, and it changes everything.

In the liver, THC (delta-9-THC) is converted into 11-hydroxy-THC (11-OH-THC) — a metabolite that crosses the blood-brain barrier more easily and may be 1.5 to 7 times more potent than delta-9-THC. This is why edibles can feel qualitatively different from smoking: more intense, more body-focused, and longer-lasting. It is also why genetics matter more for edibles than for any other form of cannabis consumption. The liver is the bottleneck, and your genes determine how fast that bottleneck processes THC.

CYP2C9 and THC Metabolism

The primary enzyme responsible for THC metabolism is CYP2C9. This enzyme handles the initial oxidation of delta-9-THC and is a key determinant of how quickly THC is processed during the first-pass effect.

CYP2C9 has well-characterized genetic variants that significantly alter enzyme activity:

• CYP2C9*1/*1 (normal metabolizer): Standard enzyme activity. THC is metabolized at the expected rate. Edibles typically kick in within 30 to 90 minutes and last 4 to 8 hours.
• CYP2C9*1/*3 or *1/*2 (intermediate metabolizer): Reduced enzyme activity. THC may be metabolized more slowly, leading to higher THC blood levels that persist longer. Edibles may feel stronger and last longer than expected.
• CYP2C9*3/*3 (poor metabolizer): Substantially reduced enzyme activity. THC clearance is significantly delayed. Studies show that individuals with the *3/*3 genotype can have THC blood levels approximately 3 times higher than *1/*1 individuals after the same dose.

The implications are significant. If you are a CYP2C9 poor metabolizer, a standard edible dose may produce blood levels far higher than intended — and those levels persist longer because your body clears THC more slowly. This can explain why some people find edibles overwhelmingly strong while others feel almost nothing from the same product.

CYP3A4: The Other Key Enzyme

CYP2C9 is not the only player. CYP3A4 also contributes to THC metabolism, particularly at higher doses when CYP2C9 becomes saturated. CYP3A4 is the most abundant drug-metabolizing enzyme in the liver and is involved in the metabolism of approximately 50% of all pharmaceutical drugs.

For THC, CYP3A4 provides a secondary pathway. If your CYP2C9 activity is reduced (due to genetic variants), your body relies more heavily on CYP3A4 to compensate. But CYP3A4 also has genetic variability, and it is heavily influenced by other substances — including grapefruit juice, certain medications, and other cannabinoids.

This dual-pathway metabolism means that your edible experience is shaped by the combined activity of both enzymes, not just one.

Why “Ultrarapid” and “Poor” Metabolizer Status Matters Here

If you have read about poor metabolizer status or ultrarapid metabolizer status in the context of prescription medications, the same framework applies to cannabis metabolism.

Poor CYP2C9 metabolizers clear THC slowly. For edibles, this typically means stronger and longer effects at any given dose. The risk of unpleasant experiences — anxiety, paranoia, excessive sedation — is higher because THC levels accumulate beyond what was intended.

Normal or rapid CYP2C9 metabolizers clear THC at a standard or accelerated rate. Edibles may feel weaker or shorter in duration. Some people in this group report that edibles “don't work” for them — they are metabolizing THC through the first pass so efficiently that relatively little reaches the brain in active form.

This explains the most common edible complaint: “I took an edible and felt nothing, so I took another one, and then it hit me like a train.” The first dose was still being processed when the second dose arrived — and the combined load overwhelmed the metabolic capacity, regardless of genotype.

What This Means for Dosing

Understanding your CYP2C9 status has practical implications for how you approach edibles:

• Start low. 2.5 to 5 mg of THC is a reasonable starting dose regardless of genetics. If you are a poor metabolizer, even 5 mg may produce strong effects.
• Wait longer than you think. The standard advice is to wait 2 hours before re-dosing. If you are a slow metabolizer, consider waiting 3 or more hours. Peak effects from edibles can occur anywhere from 1 to 4 hours after ingestion depending on food, fat content, and individual metabolism.
• Do not calibrate edible doses based on your smoking experience. They are metabolized by different pathways. Someone who tolerates smoked cannabis well may still be overwhelmed by a moderate edible dose if their CYP2C9 activity is reduced.
• Fat matters. THC is fat-soluble. Edibles consumed with a high-fat meal are absorbed more completely, increasing effective dose. This interacts with your genetic metabolism rate — a high-fat meal plus slow CYP2C9 activity is a recipe for unexpectedly intense effects.

CBD Metabolism Adds Another Layer

If your edible contains CBD (as many products do), additional genes come into play. CBD is primarily metabolized by CYP2C19 and CYP3A5 — different enzymes than the ones primarily responsible for THC.

This means your response to a THC+CBD edible is shaped by at least three to four different genes working in combination. A person who is a CYP2C9 poor metabolizer (slow THC clearance) but a CYP2C19 normal metabolizer (standard CBD clearance) will have a very different experience from someone with the opposite combination.

For a detailed look at how genetics affect CBD specifically, including the CYP3A5/CYP2C19 gene-gene interaction that predicts gastrointestinal side effects, see CBD side effects and genetics.

What Your DNA Can Tell You

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer DNA test, you already have the data needed to determine your CYP2C9 genotype and metabolizer status. DecodeMyBio's Cannabis & CBD Report analyzes CYP2C9, CYP2C19, CYP3A5, and CYP1A2 — the four pharmacogenes most relevant to cannabis metabolism — and translates your genotypes into metabolizer phenotypes with practical context.

You can view a sample Cannabis & CBD Report to see exactly what is included.